RecruitingPhase 2NCT05678270
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Principal Investigator
- Jin LiShanghai East Hospital
- Intervention
- ICP-192(drug)
- Enrollment
- 70 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (30)
- Anhui Provincial Hospital, Hefei, Anhui, China
- Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
- Beijing Youan Hosptital,Capital Medical University, Beijing, Beijing Municipality, China
- Beijing Cancer Hospital, Beijing, Beijing Municipality, China
- Beijing Hospital, Beijing, Beijing Municipality, China
- Fujian Cancer Hospital, Fujian, Fujian, China
- Fujian Medical University Union Hospital, Fuzhou, Fujian, China
- Mengchao hepatobiliary Hospital of FuJian Medical university, Fuzhou, Fujian, China
- Foshan First People's Hospital, Foshan, Guangdong, China
- Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
- ZhuJiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
- Hebei Medical University Fourth Hospital, Shijiazhuang, Hebei, China
- Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05678270 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNANCT07263217Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver InjurySecond Affiliated Hospital, School of Medicine, Zhejiang University